Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.17 Analyst target: $1.00 Upside: 494.18%
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.